The ANZCHOG ASM 2026 program will include plenary sessions, invited speaker sessions, industry involvement and concurrent paper sessions.
Please find below a preliminary copy of the 2026 ASM program as a guide of what to expect. Please note the program is subject to changes.
ANZCHOG 2026 ASM Program
- Main program
- Partner session
- Workshop
- Social function
- Breaks
|
0800-0900 |
Arrival tea & coffee / registration open |
|||
|
0900-1500 |
Pre-conference Nurse Workshop
|
Pre-conference Allied Health Workshop
|
Pre-conference Pharmacy Workshop
|
Pre-conference Fellows Workshop
|
|
Sponsored by Cure Brain Cancer Foundation  |
|
|||
|
1500-1600 |
Afternoon Tea Trade display and Poster viewing |
|||
|
1600-1630 |
Opening Ceremony |
|||
|
1630-1715 |
Plenary 1
|
|||
|
Precision Supportive Care in Pediatric Oncology
Dr Lillian Sung, The Hospital for Sick Children |
||||
|
1715-1800 |
Plenary 2
|
|||
|
Presentation title TBC Prof Matt Dun, Hunter Medical Research Institute |
||||
|
1800-1915 |
Welcome Reception in Exhibition |
|||
|
1930-2100 |
|
|||
|
|
||||
|
Sponsored by Recordati Rare Diseases  |
||||
|
0730-0830 |
Partner Breakfast Symposium |
||||
|
Sponsored by Amgen  |
Presentation title TBC A/Prof Rachel Rau, Seattle Children’s Hospital Sponsored by Amgen |
||||
|
0800-0900 |
Arrival tea & coffee / registration open |
||||
|
0900-0945 |
Plenary 3
|
||||
|
Strategies to manage relapsed/refractory high risk neuroblastoma Prof Holger Lode, Paediatrics at University Medicine Greifswald |
|||||
|
0945-1030 |
Plenary 4
|
||||
|
Prevention of Cisplatin-induced Hearing Loss: The Time is Now
Prof David Freyer, Children’s Hospital Los Angeles |
|||||
|
1030-1100 |
Morning tea Trade display and Poster viewing |
||||
|
1100-1215 |
Concurrent 1 – Oncofertility |
Concurrent 2 – Cancer Genetics |
Concurrent 3 – Allied Health |
||
|
|
1100 -1115
Patterns of Care in Paediatric Genetic Cancer Risk Clinics: A Seven-Year Review Andrew Grant, Sydney Children’s Hospital |
1100-1130
Revolutionizing Recovery: The Power of Digital-Health and Community to Scale Exercise for Childhood Cancer Survivors Dr David Mizrahi, Daffodil Centre, University of Sydney |
|||
|
1115-1130
Understanding How to Best Support Families’ Undergoing Regular Cancer Surveillance, Including Whole-Body MRI, for their Child with a Genetic Cancer Risk Jacqueline Hunter, The University of Melbourne/University of New South Wales |
|||||
|
1130-1145
The Impact of Unilateral Salpingo-Oophorectomy (USO) on Reproductive Health in Female Childhood Cancer Survivors: A Systematic review Dr Zobaida Edib, The University of Melbourne |
1130-1145
Hope and Uncertainty: Understanding Parents’ Distress During Their Child’s Participation in a Precision Medicine Trial for Poor Prognosis Cancer Dr Kate Hetherington, UNSW/SCH |
1130-1145
Embedding theory and practice for paediatric oncology social workers in a tertiary setting: A structured reflective group model Allison Rifkin, Children’s Hospital at Westmead |
|||
|
1145-1200
Building the national investment case for CAYA oncofertility: Defining the economic architecture required to implement fertility preservation guidelines in Australian oncology systems Dr Apoorva Bhargava, The University of Melbourne |
1145-1200
No survivor left behind: Integrating genetics into oncology survivorship care Tora Sibbald, The Children’s Hospital at Westmead |
1145-1200
Music Matters: An Innovative and National Music Therapy Service Supporting Paediatric Brain Cancer Recipients and their Families. Annette Baron, Robert Connor Dawes Foundation Nikki Ritchie, Sunshine Coast University Hospital |
|||
|
1200-1215
Ovarian follicle density in under 20-year oncofertility patients Dr Michael Assis, The University of Melbourne |
1200-1215
Beyond Surveillance: The Specialist Nurse Role in Identifying Psychological Distress in Paediatric Genetic Cancer Risk Andrew Grant, Sydney Children’s Hospital |
1200-1215
Redesigning High-Dose Methotrexate Pathways in Paediatric Acute Lymphoblastic Leukaemia: Safer Care through Multi-Disciplinary Collaboration Dr Lauren Madigan, Sydney Children’s Hospital |
|||
|
1215-1300 |
Focused Session 1 – Infections in Oncology
|
Focused Session 2 – Haematology
|
Focused Session 3 – Wellbeing
|
||
|
1215-1237
Antibiotic decision-making in febrile neutropenia Dr Coen Butters, John Hunter Children’s Hospital 1237-1300 Prevention of Bacterial and Fungal Infections – From Guideline to Practice Dr Lillian Sung, The Hospital for Sick Children |
1215-1237 Thrombosis and Pediatric Malignancy Dr Sally Campbell, Queensland Children’s Hospital 1237-1300 Presentation title TBC Dr Anastazia Keegan, King Edward Memorial Hospital |
1215-1237 Presentation title TBC Dr Ben Britton, University of Newcastle 1237-1300 Implementation of Group Supervision for Oncology Nurses: Caring for the Carers Dr Stephen Spencer, Rest In Essence |
|||
|
1300-1415 |
Lunch Trade display and Poster viewing |
||||
|
1315-1400 |
Partner Lunch Symposium |
||||
|
1415-1545 |
ANZCHOG Clinical Trials Update
|
||||
|
1545-1615 |
Afternoon tea Trade display and Poster viewing |
||||
|
1615-1730 |
Concurrent 4 – Neuro-Oncology |
Concurrent 5 – Leukaemias |
Concurrent 6 – Supportive Care |
||
|
1615-1630
Leveraging the Immunomodulatory Effects of Dordaviprone to Induce Adaptive Immune Infiltration in Diffuse Midline Glioma Dr Mika Persson, University of Newcastle |
1615-1630
Gut Microbiome Modulation Restores Tyrosine Kinase Inhibitor Efficacy in High-Risk Acute Lymphoblastic Leukaemia Pre-Clinical Models Dr Elyse Page, SAHMRI |
1615-1645
Work on a knife edge- negotiating specialist palliative care for an AYA population Dr Abigail Franklin, Northern Sydney Local Health District |
|||
|
1630-1645
Clinical and Molecular characteristics of Paediatric Clival Chordomas: A Single Institution Retrospective Study Dr Sumanth Nagabushan, Cancer Centre for Children Children’s Hospital at Westmead |
1630-1645
Kids Oncology And Leukaemia or Allograft – PharmacoKinetics (KOALA-PK): A Study Protocol Claire Moore, Murdoch Children’s Research Institute |
||||
|
1645-1700
Paediatric Central Nervous System Tumours in First Nations Children: Global Inequities in Incidence and Survival Eden Slicer, Telethon Kids Institute |
1645-1700
Ultrasensitive personalised panel sequencing (UPPseq) for blood minimal residual disease monitoring in leukaemia Dr Sarah Trinder, Perth Children’s Hospital; Children’s Cancer Institute at Minderoo Children’s Comprehensive Cancer Centre |
1645-1700
Early insights, better outcomes: Refining paediatric palliative care referral through a timely decision-making guideline. Annette Vickery, Palliative Care Australia |
|||
|
1700-1715
Enhancing immunotherapeutic response in high risk medulloblastoma through integration of ATR inhibition, craniospinal irradiation, and CD47 blockade Dr Meegan Howlett, The Kids Institute Australia |
1700-1715
Contemporary Treatment Costs of Childhood Acute Lymphoblastic Leukaemia in Australia Dr Karen McCleary, Sydney Children’s Hospital |
1700-1715
Otoprotection At What Cost? Acute Adverse Effects of Sodium Thiosulfate in Cisplatin-Treated Patients Dr Andrea Zhu, The Royal Children’s Hospital |
|||
|
1715-1730
High-throughput 3D modelling of medulloblastoma identifies a repurposed CNS drug targeting MYC-driven disease Dr Iman Azimi, Monash University |
1715-1730
Antifungal Prophylaxis Patterns and Invasive Fungal Infections Outcomes in Paediatric Allogenic HCT: A Multicentre Cohort Study Hyatt Assafiri, The Royal Children’s Hospital |
1715-1730
SPARK: Paediatric Audiovisual Distraction Device Aimee Welch, Radiation Oncology Mater Hospital Raymond Terrace |
|||
|
1900-0000 |
Gala Dinner
|
||||
|
0730-0830 |
Partner Breakfast Symposium |
||
|
0800-0900 |
Arrival tea & coffee / registration open |
||
|
0900-1000 |
ANZCHOG ASM Best Abstracts
|
||
|
0900 – 0915
Leveraging Integrated Proteogenomics to Address Molecular Heterogeneity in the Treatment of Diffuse Midline Glioma Izac Findlay, University of Newcastle |
|||
|
0900 – 0915
Leveraging Integrated Proteogenomics to Address Molecular Heterogeneity in the Treatment of Diffuse Midline Glioma Izac Findlay, University of Newcastle |
|||
|
0915 – 0930
Ultrasensitive whole-genome-based, tumour-informed circulating tumour DNA detection correlates with treatment response and outcome in paediatric solid tumour A/Prof Loretta Lau, Children’s Cancer Institute |
|||
|
0930-0945
Efficacy and Tolerability of Trametinib in the Treatment of Plexiform Neurofibroma in Children, Adolescents and Young Adults – Results of the TiNT Study, a phase 2 trial Dr Andrew Dodgshun, Christchurch Hospital |
|||
|
0945-1000
Decoding Childhood Cancer: Interplay of Germline Risk and Somatic Drivers Dr Noemi Fuentes Bolanos, Kids Cancer Centre. Sydney Children’s Hospital |
|||
|
1000-1115 |
Concurrent 7 – Solid Tumours |
Concurrent 8 – Survivorship |
Concurrent 9 – Psychosocial |
|
1000-1015
Delphi consensus recommendations for second opinion seeking in paediatric oncology Dr Hilary Cahill, Royal Manchester Children’s Hospital |
1000-1015
Long-Term Obesity Risk in Childhood Cancer Survivors in Singapore: A Retrospective Audit Dr Yuan Rui Leon Tan, Kk Women’s And Children’s Hospital |
|
|
|
1015-1030
Mapping the Proton Beam Therapy Referral Pathway: A quality assurance evaluation at a tertiary paediatric oncology centre Dr Eun Ji Hwang, Westmead Hospital |
1015-1030
Provision of Information and Resources After Childhood Cancer Treatment: ‘What Happens Now?’ Christine Cashion, QCH and QUT |
1000-1015
“We are broken”: Highlighting the need to integrate financial support into paediatric cancer care Dr Axelle Marjolin, Redkite |
|
|
1030-1045
Identifying molecular mechanisms of cisplatin resistance in osteosarcoma using functional genomic screening and multiomic profiling of in vitro models. Dr Elise Young, Hudson Institute of Medical Research |
1030-1045
Enhancing radiotherapy with DNA damage response inhibitors in medulloblastoma: Balancing cure and neurodevelopmental outcomes Dr Annabel Short, The Kids Research Institute Australia |
1030-1045
A holistic approach to psychosocial support for parents and families of paediatric cancer patients in Aotearoa New Zealand: The National Child Cancer Counselling Network. Prof Kirsty Ross, Massey University |
|
|
1045-1100
Outcomes of multisystem Langerhans cell histiocytosis in Australian children: a single-centre retrospective study Dr Clare Parker, Royal Children’s Hospital, Melbourne |
1045-1100
Self-reported cognitive and educational impacts among survivors of child, adolescent and young adult cancer A/Prof Joanna Fardell, University of New South Wales |
1045-1100
Digital Support for Parents of Children and Adolescents with Cancer: Lessons from the Compass Program Pilot Rhiannon Edge, Redkite |
|
|
1100-1115
The Australian Pharmacogenetic Paediatric Oncology Network for Drug Safety – a national genomic infrastructure for AI driven discovery Prof Rachel Conyers, Murdoch Children’s Research Institute |
1100-1115
Patient and family voices on childhood cancer survivorship: Identifying unmet needs across the survivorship continuum Dr Udani Reets, Children’s Cancer CoLab |
1100-1115
Integrating SSPedi Patient-Reported Outcomes into Early-Phase Paediatric Precision Oncology Trials: Feasibility Insights from PROptimise Dr Denise Connolly, Sydney Children’s Hospital |
|
|
1115-1200 |
Morning tea Trade display and Poster viewing |
||
|
|
Partner Morning Symposium
|
Partner Morning Symposium
|
|
|
1130-1200
Sponsored by Jazz Pharmaceuticals  |
1130-1200
Presentation title TBC Prof David Freyer, Children’s Hospital Los Angeles Sponsored by Norgine 
|
||
|
1200-1245 |
Focused Session 4 – Vascular Malformation & Role of Surgeries in Clinical Trials |
Focused Session 5 – Bone Marrow Failure Syndrome & Haematology
|
|
|
1200-1222
Presentation title TBC Dr David Lord, John Hunter Children’s Hospital 1222-1245 Presentation title TBC Prof Jonathan Karpelowsky, Children’s Hospital at Westmead/ University of Sydney |
1200-1222
The Genomic Blueprint of ALL: Masterpiece…or a Work in Progress? Prof Deborah White, South Australian Health and Medical Research Institute 1222-1245 Whole genome transcriptome sequencing in inherited bone marrow failure syndromes: The IBMDx study Dr Lucy Fox, Peter MacCallum Cancer Centre |
||
|
1245-1330 |
Plenary 7 |
||
|
1330-1400 |
Closing Ceremony |
||
